Metabolic signature of breast cancer cell line MCF-7: Profiling of modified nucleosides via LC-IT MS coupling

BMC Biochemistry

Volumn 8, Issue , 2007, Pages

  Bullinger, Dino ^a   Neubauer, Hans ^a   Fehm, Tanja ^a   Laufer, Stefan ^b   Gleiter, Christoph H ^a   Kammerer, Bernd ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 RIBOSYL 4 CARBOXAMIDO 5 AMINOIMIDAZOLE; 3 (3 AMINOCARBOXYPROPYL)URIDINE; 5 METHYLURIDINE; I RIBOSYLIMIDAZOLE 4 ACETIC ACID; N 2,N 2,7 TRIMETHYLGUANOSINE; N 6 METHYL N 6 THREONYLCARBAMOYLADENOSINE; RIBONUCLEOSIDE; S ADENOSYLMETHIONINE; UNCLASSIFIED DRUG; 3-(3-AMINO-3-CARBOXYPROPYL)URIDINE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENOSINE; DRUG DERIVATIVE; GUANOSINE; IMIDAZOLE DERIVATIVE; ION; ISOGUANOSINE; N(2),N(2) DIMETHYLGUANOSINE; N(2),N(2)-DIMETHYLGUANOSINE; N6 METHYL N6 THREONYLCARBAMOYLADENOSINE; N6-METHYL-N6-THREONYLCARBAMOYLADENOSINE; NUCLEOSIDE X; RIBOSE; RIBOSYLIMIDAZOLE ACETIC ACID; RIBOTHYMIDINE; TUMOR MARKER; URIDINE;

ARTICLE; BREAST CANCER; CELL METABOLISM; CELL STRAIN MCF 7; CHEMICAL STRUCTURE; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; RNA METABOLISM; TIME OF FLIGHT MASS SPECTROMETRY; BREAST TUMOR; CELL LINE; CYTOLOGY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; MAMMARY GLAND; METABOLISM; STANDARD; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE;

ADENOSINE; AMINOIMIDAZOLE CARBOXAMIDE; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; EPITHELIAL CELLS; FEMALE; GUANOSINE; HUMANS; IMIDAZOLES; IONS; MAMMARY GLANDS, HUMAN; METABOLIC NETWORKS AND PATHWAYS; RIBONUCLEOSIDES; RIBOSE; S-ADENOSYLMETHIONINE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL; URIDINE;

EID: 38849115197     PISSN: None     EISSN: 14712091     Source Type: Journal    
DOI: 10.1186/1471-2091-8-25     Document Type: Article

References (59)

1. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. JL Khatcheressian AC Wolff TJ Smith E Grunfeld HB Muss VG Vogel F Halberg MR Somerfield NE Davidson, J Clin Oncol 2006 24 5091 5097 10.1200/JCO.2006.08.8575 17033037
2. So what's the deal with metabonomics? JC Lindon E Holmes JK Nicholson, Anal Chem 2003 75 384A 391A 14632032
3. Transfer RNA modification. GR Bjork JU Ericson CE Gustafsson TG Hagervall YH Jonsson PM Wikstrom, Annu Rev Biochem 1987 56 263 287 10.1146/annurev.bi.56. 070187.001403 3304135
4. The RNA modification database - 1998. JA McCloskey PF Crain, Nucleic Acids Res 1998 26 196 197 9399834 10.1093/nar/26.1.196
5. Urinary nucleosides. KH Schram, Mass Spectrom Rev 1998 17 131 251 10.1002/(SICI)1098-2787(1998)17:3<131::AID-MAS1>3.0.CO;2-O 10095827
6. Modified nucleosides in human serum. EP Mitchell L Evans P Schultz R Madsen JW Yarbro CW Gehrke K Kuo, J Chromatogr 1992 581 31 40 10.1016/0378-4347(92)80444-U 1430005
7. Chromatographic, capillary electrophoretic and matrix-assisted laser desorption ionization time-of-flight mass spectrometry analysis of urinary modified nucleosides as tumor markers. HM Liebich S Mueller-Hagedorn F Klaus K Meziane KR Kim A Frickenschmidt B Kammerer, Journal of Chromatography, A 2005 1071 271 275 10.1016/j.chroma.2004.12.055
8. Major and modified nucleosides in tRNA hydrolysates by high-performance liquid chromatography. GE Davis CW Gehrke KC Kuo PF Agris, J Chromatogr 1979 173 281 298 10.1016/S0021-9673(00)92297-0 94916
9. Biological markers in breast carcinoma - clinical correlations with pseudouridine, N2,N2-dimethylguanosine, and 1-methylinosine. DC Tormey TP Waalkes CW Gehrke, J Surg Oncol 1980 14 267 273 10.1002/jso.2930140313 7392649
10. Relationship of urinary pseudouridine and 1-methyladenosine to activity of leukemia and lymphoma. K Itoh T Konno T Sasaki S Ishiwata N Ishida M Misugaki, Clin Chim Acta 1992 206 181 189 10.1016/0009-8981(92)90087-7 1606704
11. Reversed-phase high-performance liquid chromatographic investigation of mucosal nucleosides and bases and urinary modified nucleosides of gastrointestinal cancer patients. K Nakano K Shindo T Yasaka H Yamamoto, J Chromatogr 1985 343 21 33 10.1016/S0378-4347(00)84564-8 4066857
12. Modified ribonucleosides as biological markers for patients with small cell carcinoma of the lung. TP Waalkes MD Abeloff DS Ettinger KB Woo CW Gehrke KC Kuo E Borek, Eur J Cancer Clin Oncol 1982 18 1267 1274 10.1016/0277-5379(82) 90128-6 6299748
13. Two approaches for determining the urinary excretion patterns of nucleosides - HPLC and CE. G Xu X Lu Y Zhang P Lu SC Di R Lehmann H Liebich, Se Pu 1999 17 97 101 12549143
14. Mass spectrometric identification of modified urinary nucleosides used as potential biomedical markers by LC-ITMS coupling. B Kammerer A Frickenschmidt CE Muller S Laufer CH Gleiter H Liebich, Anal Bioanal Chem 2005 382 1017 1026 10.1007/s00216-005-3232-2 15906010
15. Analysis of urinary nucleosides. I. Optimisation of high performance liquid chromatography/electrospray mass spectrometry. E Dudley S El-Sharkawi DE Games RP Newton, Rapid Commun Mass Spectrom 2000 14 1200 1207 10.1002/1097-0231(20000730)14:14<1200::AID-RCM10>3.0.CO;2-I 10918368
16. Structural characterization of modified nucleosides in tRNA hydrolysates by frit-fast atom bombardment liquid chromatography/mass spectrometry. N Takeda M Nakamura H Yoshizumi A Tatematsu, Biol Mass Spectrom 1994 23 465 474 10.1002/bms.1200230803 7522577
17. Identification of urinary nucleosides by ESI-TOF-MS. D Bullinger A Frickenschmidt M Pelzing T Zey G Zurek S Laufer B Kammerer, LC-GC Europe 2005 16 17
18. MALDI-TOF MS analysis of urinary nucleosides. B Kammerer A Frickenschmidt CH Gleiter S Laufer H Liebich, J Am Soc Mass Spectrom 2005 16 940 947 10.1016/j.jasms.2005.02.018 15907708
19. Artificial neural network classification based on high-performance liquid chromatography of urinary and serum nucleosides for the clinical diagnosis of cancer. J Yang G Xu H Kong Y Zheng T Pang Q Yang, J Chromatogr B Analyt Technol Biomed Life Sci 2002 780 27 33 10.1016/S1570-0232(02)00408-7 12383477
20. Clinical significance and prognostic value of urinary nucleosides in breast cancer patients. Y Zheng H Kong J Xiong S Lv G Xu, Clin Biochem 2005 38 24 30 10.1016/j.clinbiochem.2004.09.021 15607313
21. Urinary nucleosides as potential tumor markers evaluated by learning vector quantization. F Dieterle S Muller-Hagedorn HM Liebich G Gauglitz, Artif Intell Med 2003 28 265 279 10.1016/S0933-3657(03)00058-7 12927336
22. Summary: the modified nucleosides of RNA. PA Limbach PF Crain JA McCloskey, Nucleic Acids Res 1994 22 2183 2196 7518580 10.1093/nar/22.12.2183
23. Role of ribothymidine in mammalian tRNAPhe. BA Roe HY Tsen, Proc Natl Acad Sci U S A 1977 74 3696 3700 269424 10.1073/pnas.74.9.3696
24. Three modifications in the D and T arms of tRNA influence translation in Escherichia coli and expression of virulence genes in Shigella flexneri. J Urbonavicius MB Durand Jerome GR Bjork, J Bacteriol 2002 184 5348 5357 12218021 10.1128/JB.184.19.5348-5357.2002
25. The trimethyl-guanosine cap is a nuclear targeting signal for snRNPs. AL Lamond, Trends Biochem Sci 1990 15 451 452 10.1016/0968-0004(90)90292-J 2150241
26. Small regulatory RNAs in mammals. JS Mattick I Makunin V, Hum Mol Genet 2005 14 Spec No 1 R121 R132 10.1093/hmg/ddi101 15809264
27. Challenging the dogma: the hidden layer of non-protein-coding RNAs in complex organisms. JS Mattick, BioEssays 2003 25 930 939 10.1002/bies.10332 14505360
28. Synthesis properties of the naturally occurring N-[(9-beta-D- ribofuranosylpurin-6-yl)-N-methylcarbamoyl]-L-threonine (mt-6A) and other related synthetic analogs. SP Dutta C Hong I GP Murphy A Mittelman GB Chheda, Biochemistry 1975 14 3144 3151 10.1021/bi00685a017 1148194
29. The methyl group of the N6-methyl-N6-threonylcarbamoyladenosine in tRNA of Escherichia coli modestly improves the efficiency of the tRNA. Q Qian JF Curran GR Bjork, J Bacteriol 1998 180 1808 1813 9537379
30. The effect of chemical modification of 3-(3-amino-3-carboxypropyl)uridine on tRNA function. S Friedman, J Biol Chem 1979 254 7111 7115 378998
31. S-adenosylmethionine: nothing goes to waste. M Fontecave M Atta E Mulliez, Trends Biochem Sci 2004 29 243 249 10.1016/j.tibs.2004.03.007 15130560
32. Transfer RNA base composition studies in Morris hepatomas and rat liver. E Randerath LL Chia HP Morris K Randerath, Cancer Res 1974 34 643 653 4359886
33. TRNA methylases in tumors of animal and human origin. E Tsutsui PR Srinivasan E Borek, Proc Natl Acad Sci U S A 1966 56 1003 1009 4291222 10.1073/pnas.56.3.1003
34. Links between tRNA modification and metabolism and modified nucleosides as tumor markers. GR Björk T Rasmuson, Modification and Editing of RNA Washington, American Society for Microbiology, Grosjean H and Benne R, 1998 471 491
35. High turnover rate of transfer RNA in tumor tissue. E Borek BS Baliga CW Gehrke CW Kuo S Belman W Troll TP Waalkes, Cancer Res 1977 37 3362 3366 884680
36. Metabolism of 5'-methylthioadenosine in methionine-dependent and methionine-independent cells. L Christa J Kersual JL Perignon PH Cartier, Adv Exp Med Biol 1986 195 Pt B 651 657 3766246
37. Competing methyltransferase systems. SJ Kerr, J Biol Chem 1972 247 4248 4252 4338482
38. Isolation and characterization of a novel nucleoside from the urines of chronic myelogenous leukemia patients. GB Chheda HB Patrzyc AK Bhargava PF Crain SK Sethi JA McCloskey SP Dutta, Nucleosides & Nucleotides 1987 6 597 611 10.1080/07328318708069989
39. Biologic markers in breast carcinoma: clinical correlations with urinary polyamines. DC Tormey TP Waalkes KC Kuo CW Gehrke, Cancer 1980 46 741 747 10.1002/1097-0142(19800815)46:4<741::AID-CNCR2820460418>3.0.CO;2-7 7397636
40. Polyamines in mammalian tumors. Part I. G Scalabrino ME Ferioli, Adv Cancer Res 1981 35 151 268 7041538
41. Regulation of S-adenosylmethionine decarboxylase activity by alterations in the intracellular polyamine content. LM Shantz I Holm OA Janne AE Pegg, Biochem J 1992 288 ( Pt 2) 511 518 1463454
42. Abnormal regulation of methylthioadenosine and polyamine metabolism in methylthioadenosine phosphorylase-deficient human leukemic cell lines. N Kamatani DA Carson, Cancer Res 1980 40 4178 4182 6781742
43. Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. SA Christopher P Diegelman CW Porter WD Kruger, Cancer Res 2002 62 6639 6644 12438261
44. Strong expression of methylthioadenosine phosphorylase (MTAP) in human colon carcinoma cells is regulated by TCF1/[beta]-catenin. F Bataille G Rogler K Modes I Poser M Schuierer W Dietmaier P Ruemmele M Muhlbauer S Wallner C Hellerbrand A Bosserhoff, Lab Invest 2005 85 124 136 15492751
45. Targeting 5'-deoxy-5'-(methylthio)adenosine phosphorylase by 5'-haloalkyl analogues of 5'-deoxy-5'-(methylthio)adenosine. JR Sufrin AJ Spiess DL Kramer PR Libby JT Miller RJ Bernacki YH Lee RT Borchardt CW Porter, J Med Chem 1991 34 2600 2606 10.1021/jm00112a039 1908523
46. Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. J Swinnen V A Beckers K Brusselmans S Organe J Segers L Timmermans F Vanderhoydonc L Deboel R Derua E Waelkens SE De ST Van de A Noel F Foufelle G Verhoeven, Cancer Res 2005 65 2441 2448 10.1158/0008-5472.CAN-04-3025 15781660
47. 5 '-Amino-4-imidazolecarboxamide riboside induces apoptosis in human neuroblastoma cells via the mitochondrial pathway. M Garcia-Gil F Bertini R Pesi V Voccoli MG Tozzi M Camici, Nucleosides Nucleotides Nucleic Acids 2006 25 1265 1270 10.1080/15257770600890905 17065104
48. Changes in histamine synthesis, tissue content and catabolism in human breast cancer. M Garcia-Caballero E Neugebauer F Rodriguez C Nunez I A Heredia E Oosting TC Vara, Agents Actions 1989 27 227 231 10.1007/BF02222247 2750594
49. Demonstration of histamine H2 receptors on human melanoma cells. RJ Whitehead DJ Taylor JM Evanson IR Hart DE Woolley, Biochem Biophys Res Commun 1988 151 518 523 2831890
50. Involvement of histamine in growth of mouse and rat tumors: antitumoral properties of monofluoromethylhistidine, an enzyme-activated irreversible inhibitor of histidine decarboxylase. J Bartholeyns M Bouclier, Cancer Res 1984 44 639 645 6692368
51. Effect of mast cell products and histamine on the proliferative behaviour of human melanoma and carcinoma cells in vitro. DE Woolley D Eckley LC Tetlow RJ Whitehead, Agents Actions 1993 38 C182 C184 10.1007/BF01996453
52. Stimulation of histamine synthesis from tumour cells by concanavalin A and A23187. H Nolte SP Stahl H Loft, Agents Actions 1987 20 291 294 10.1007/BF02074694 3111197
53. Histamine in human breast cancer. JL Reynolds JA Akhter CJ Magarey P Schwartz WJ Adams DL Morris, Br J Surg 1998 85 538 541 10.1046/j.1365-2168.1998. 00625.x 9607543
54. A human cell line from a pleural effusion derived from a breast carcinoma. HD Soule J Vazguez A Long S Albert M Brennan, J Natl Cancer Inst 1973 51 1409 1416 4357757
55. The process of malignant progression in human breast cancer. R Clarke RB Dickson N Brunner, Ann Oncol 1990 1 401 407 2083184
56. Defects in methylthioadenosine phosphorylase are associated with but not responsible for methionine-dependent tumor cell growth. B Tang YN Li WD Kruger, Cancer Res 2000 60 5543 5547 11034100
57. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. HD Soule TM Maloney SR Wolman WD Peterson Jr. R Brenz CM McGrath J Russo RJ Pauley RF Jones SC Brooks, Cancer Res 1990 50 6075 6086 1975513
58. Ultrastructural and immunocytochemical characterization of an immortalized human breast epithelial cell line, MCF-10. L Tait HD Soule J Russo, Cancer Res 1990 50 6087 6094 1697506
59. Quantitation of urinary nucleosides by high-performance liquid chromatography. HM Liebich SC Di A Wixforth HR Schmid, J Chromatogr A 1997 763 193 197 10.1016/S0021-9673(96)00757-1 9129323